INT102578

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2002
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 22
Total Number 24
Disease Relevance 10.39
Pain Relevance 0.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (HBE1) transport (HBE1)
Anatomy Link Frequency
liver 2
blood 1
HBE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 1 96.40 Very High Very High Very High
Pain 6 94.68 High High
cva 1 93.36 High High
nud 1 90.96 High High
fibrosis 15 86.12 High High
Inflammation 39 85.64 High High
Potency 69 46.24 Quite Low
Serotonin 5 6.24 Low Low
peripheral neuropathy 24 5.00 Very Low Very Low Very Low
Spinal cord 12 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hepatitis 418 99.72 Very High Very High Very High
Hepatitis B Virus Infection 949 99.26 Very High Very High Very High
Pain 6 94.68 High High
Stress 35 94.56 High High
Gastritis 1 93.40 High High
Cv General 3 Under Development 1 93.36 High High
Chronic Hepatitis B 9 91.36 High High
Dyspepsia 1 90.96 High High
Infection 87 90.88 High High
Emergencies 2 90.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The HB mRNA level was then included as an additional covariate in the original model, and thus the expression difference of HBE and HEBP1 was evaluated taking the maximum perfusion effect into account.


Gene_expression (expression) of HBE
1) Confidence 0.47 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1858698 Disease Relevance 0 Pain Relevance 0
We found that four of the five investigated genes, HBA, HBB, HBE and HEBP1, showed decreased expression levels in foxes selected for tameness compared to non-selected farm foxes.
Gene_expression (expression) of HBE
2) Confidence 0.47 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1858698 Disease Relevance 0 Pain Relevance 0
Thus to evaluate the potential effect of blood perfusion on HBE and HEBP1 expression levels, we assumed that the average HBA and HBB levels (HB) could represent the maximum effect of blood perfusion caused by e.g. a systemic stress response.
Gene_expression (expression) of HBE in blood associated with stress
3) Confidence 0.47 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1858698 Disease Relevance 0.09 Pain Relevance 0
For three of the genes, HBA, HBE and HEBP1, an additive genetic component did indeed appear to explain the observed expression variation.
Gene_expression (expression) of HBE
4) Confidence 0.41 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1858698 Disease Relevance 0 Pain Relevance 0
However, HBA and HBB differences between S and NS foxes could only partly account for the observed decreased levels of HBE and HEBP1 in selected foxes.
Gene_expression (levels) of HBE
5) Confidence 0.36 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1858698 Disease Relevance 0.19 Pain Relevance 0
In both phase III HBeAg positive and HBeAg negative studies, the degree of viral load suppression at the end of treatment was higher in those on a lamivudine-containing regimen than those on pegylated interferon alpha-2a alone (7.2 log vs 4.5 log respectively in the HBeAg positive study and 5.0 log vs 4.1 log respectively in the HBeAg negative study), but the rate of sustained disease remission was higher in the latter (Marcellin et al 2004; Lau, Piratvisuth, et al 2005).
Gene_expression (positive) of HBeAg associated with disease
6) Confidence 0.04 Published 2006 Journal International Journal of Nanomedicine Section Body Doc Link PMC2426802 Disease Relevance 0.14 Pain Relevance 0
The largest of these was the phase III international GLOBE trial, which enrolled 1370 HBeAg-positive and HBeAg-negative antiviral-naïve subjects and randomized them to receive either 600 mg of telbivudine or 100 mg of lamivudine once daily.14 A second phase III trial (study 015), identical in design and intervention, enrolled 332 patients in China only.15 Telbivudine has also been compared to adefovir in randomized, open-label study in HBeAg-positive patients (study 018).16
Gene_expression (enrolled) of HBeAg
7) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.59 Pain Relevance 0.03
The largest of these was the phase III international GLOBE trial, which enrolled 1370 HBeAg-positive and HBeAg-negative antiviral-naïve subjects and randomized them to receive either 600 mg of telbivudine or 100 mg of lamivudine once daily.14 A second phase III trial (study 015), identical in design and intervention, enrolled 332 patients in China only.15 Telbivudine has also been compared to adefovir in randomized, open-label study in HBeAg-positive patients (study 018).16
Neg (negative) Gene_expression (positive) of HBeAg
8) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.63 Pain Relevance 0.03
All had maintained HBeAg loss, but only 93% maintained HBeAg seroconversion.
Gene_expression (loss) of HBeAg
9) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.35 Pain Relevance 0
In this study, telbivudine showed a more potent HBV DNA reduction at one year compared to lamivudine in both HBeAg-positive and HBeAg-negative patients, with an average drop of ?
Gene_expression (positive) of HBeAg associated with hepatitis b virus infection
10) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.63 Pain Relevance 0
ALT normalization occurred commonly with telbivudine and lamivudine in both HBeAg-positive and HBeAg-negative subjects.
Gene_expression (positive) of HBeAg
11) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.18 Pain Relevance 0.03
The largest of these was the phase III international GLOBE trial, which enrolled 1370 HBeAg-positive and HBeAg-negative antiviral-naïve subjects and randomized them to receive either 600 mg of telbivudine or 100 mg of lamivudine once daily.14 A second phase III trial (study 015), identical in design and intervention, enrolled 332 patients in China only.15 Telbivudine has also been compared to adefovir in randomized, open-label study in HBeAg-positive patients (study 018).16
Neg (negative) Gene_expression (positive) of HBeAg
12) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.58 Pain Relevance 0.03
ALT normalization occurred commonly with telbivudine and lamivudine in both HBeAg-positive and HBeAg-negative subjects.
Gene_expression (positive) of HBeAg
13) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.18 Pain Relevance 0.03
Secondary outcomes were histologic response, change in HBV DNA levels, HBeAg loss, HBsAg loss, HBeAg seroconversion, HBsAg seroconversion, and normalization of ALT.
Gene_expression (seroconversion) of HBeAg associated with hepatitis b virus infection
14) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.56 Pain Relevance 0
The largest of these was the phase III international GLOBE trial, which enrolled 1370 HBeAg-positive and HBeAg-negative antiviral-naïve subjects and randomized them to receive either 600 mg of telbivudine or 100 mg of lamivudine once daily.14 A second phase III trial (study 015), identical in design and intervention, enrolled 332 patients in China only.15 Telbivudine has also been compared to adefovir in randomized, open-label study in HBeAg-positive patients (study 018).16
Gene_expression (enrolled) of HBeAg
15) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.64 Pain Relevance 0.03
In this study, telbivudine showed a more potent HBV DNA reduction at one year compared to lamivudine in both HBeAg-positive and HBeAg-negative patients, with an average drop of ?
Gene_expression (positive) of HBeAg associated with hepatitis b virus infection
16) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.63 Pain Relevance 0
In both phase III HBeAg positive and HBeAg negative studies, the degree of viral load suppression at the end of treatment was higher in those on a lamivudine-containing regimen than those on pegylated interferon alpha-2a alone (7.2 log vs 4.5 log respectively in the HBeAg positive study and 5.0 log vs 4.1 log respectively in the HBeAg negative study), but the rate of sustained disease remission was higher in the latter (Marcellin et al 2004; Lau, Piratvisuth, et al 2005).
Gene_expression (positive) of HBeAg associated with disease
17) Confidence 0.04 Published 2006 Journal International Journal of Nanomedicine Section Body Doc Link PMC2426802 Disease Relevance 0.14 Pain Relevance 0
In the phase III HBeAg positive study, 814 HBeAg positive chronic HBV-infected patients were randomized to receive either pegylated interferon alpha-2a 180 ?
Gene_expression (study) of HBeAg associated with hepatitis b virus infection
18) Confidence 0.04 Published 2006 Journal International Journal of Nanomedicine Section Body Doc Link PMC2426802 Disease Relevance 0.49 Pain Relevance 0.03
Of the 38 telbivudine patients who elected to do so, 82% sustained HBeAg loss through the last study visit after a median post-treatment follow up of 29.1 weeks.19
Gene_expression (loss) of HBeAg
19) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.44 Pain Relevance 0
6.45 log copies/mL drop in HBeAg-positive patients and ?
Gene_expression (drop) of HBeAg
20) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.57 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox